查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863341

下一代体外诊断市场按产品类型、技术、最终用户、应用、测试类型和检体类型划分－2025年至2032年全球预测

Next-Generation IVD Market by Product Type, Technology, End User, Application, Test Type, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，下一代体外诊断市场将成长至 1,002 亿美元，复合年增长率为 5.43%。

关键市场统计数据
基准年 2024 656亿美元
预计年份：2025年 692.4亿美元
预测年份 2032 1002亿美元
复合年增长率 (%) 5.43%

技术融合、不断变化的法规和变革性的医疗保健服务这三大力量正在推动诊断策略的根本性转变，重塑产业相关人员。

体外诊断业界正处于快速技术创新、医疗服务模式变革以及对诊断速度、准确性和数据整合日益增长的需求交汇点。临床相关人员不仅需要能够提供准确结果的诊断解决方案，还需要这些方案能够无缝整合到诊疗流程中，支援分散式检查，并实现人群层面的监测。分子诊断技术的成熟、数位健康工具的普及以及就地检验的扩展，正迫使各机构重新评估其产品蓝图、伙伴关係和供应链策略，以保持竞争力。

法规结构和支付方的期望都在同步演变，更加强调临床效用、真实世界数据和互通性。这些变化迫使製造商加大对检验研究、品管和上市后资料收集的投入。此外，医疗机构和实验室正在调整服务模式，以平衡集中式高通量检测和床边诊断，这需要灵活的设备、耗材策略和维护模式。

在此背景下，竞争优势日益取决于能否将强大的分析效能与精简的工作流程、灵活的软体以及能够降低整体拥有成本的服务相结合。能够有效将新兴科学转化为临床相关且易于部署的解决方案的公司，将在诊断实验室、医院和诊所网路、照护现场以及研究机构中获得更大的影响力。本分析引言概述了影响因素，并为深入探讨变革性转变、贸易政策的影响、市场区隔洞察以及区域性考量奠定了基础。

识别能够颠覆传统诊断模式、开闢临床影响和商业性差异化新途径的关键技术和营运变革。

技术融合、新的临床重点以及对可操作数据的关注正在推动多项变革性转变，从根本上改变体外诊断的发展轨迹。首先，分子诊断已从专业实验室走向常规临床应用，聚合酵素链锁反应平台和等温扩增技术能够快速且灵敏地检测传染性病原体和基因标记。这项转变引发了检测化学和试剂设计的革新，重点在于提高在分布式环境下的稳定性。

其次，数位化整合和资料管理已成为核心差异化因素。将设备输出与实验室资讯系统、云端基础分析工具和决策支援工具连接起来，能够实现患者长期追踪、人群监测和人工智慧辅助解读，进而提升诊断价值。互通性标准和网路安全措施已成为软体供应商和设备製造商的核心设计要求。

第三，就地检验的普及反映了医疗服务模式的转变，强调在门诊、急诊和社区医疗机构进行快速诊断。这一趋势正在重塑产品设计，使其更加重视便携性、简化的工作流程和低维护成本。同时，服务模式也在不断发展，包括基于结果的维护、远距离诊断和基于订阅的试剂供应，从而使医疗服务提供者和供应商之间的奖励更加一致。

最后，监管和报销环境也在不断调整，以适应创新检测和数位诊断技术，这要求製造商不仅要提供分析检验，还要提供真实世界证据。这些变化需要一种整体性的商业性策略，在创新与供应链、生产扩充性和上市后支援等实际因素之间取得平衡。

分析近期美国关税如何重塑诊断设备和试剂整个生命週期的采购、定价结构和供应链韧性。

2025年美国关税的累积影响正对诊断价值链的各个环节施加多方面的压力，促使企业重新评估采购、定价和在地化策略。关键仪器组件、试剂原料和成品的关税加剧了投入成本的波动，并增加了製造商和实验室的采购复杂性。为此，许多公司正在审查其供应商网络，以减少对关税风险地区的依赖，并加快製造地的多元化。

除了直接的成本影响外，关税也在影响医疗设备的采购行为。医疗机构在考虑购买医疗设备时，现在会考虑长期总成本，包括潜在的进口关税、物流前置作业时间和维护零件的供应情况。这促使人们更加关注国产设备以及关键零件来自免税地区的设备。此外，人们也越来越重视能够保证零件和试剂稳定供应的服务合同，以抵消关税造成的价格波动。

从策略角度来看，关税正促使企业重新关注供应链韧性和垂直整合。各公司正在探索关键试剂的国内生产和本地组装，以稳定交货时间并保持竞争力。同时，区域监管和贸易政策的变化也带来了行政上的复杂性，要求製造商遵循不同的合规途径并提交不同的文件，以获得关税豁免和优惠待遇。

综合来看，2025 年的关税环境已经将决策从短期采购授予转向长期供应链重组、供应商伙伴关係以及强调模组化、本地支援和可预测的生命週期经济效益的产品策略。

分析包括产品、技术、最终用户、应用、检体类型和样本类型在内的多维度细分，以确定目标商业化需求和临床优先事项。

透过详细的市场区隔方法，可以揭示不同产品类型、技术、最终用户、应用、检体类型和样本类型所带来的差异化需求、采用模式和商业化路径。按产品类型划分，市场格局包括化学分析仪、免疫检测和PCR仪等仪器；涵盖临床化学试剂、免疫检测仪和分子诊断剂的试剂和试剂套件；以及数据管理平台和维护服务等软体和服务。每种产品类型都需要不同的市场推广模式：仪器主要依靠资本支出销售，试剂主要依靠重复消费和供应链优化，而软体和服务则主要依靠整合和生命週期收入。

技术细分突显了底层技术的多样性，包括依赖电化学或光强度检测的临床化学平台；采用化学发光免疫分析 (CLIA)、酶联免疫吸附试验 (ELISA) 和流动注射分析 (FIA) 等形式的免疫检测系统；从基于培养的方法到分子检测的各种微生物学方法；以及包括等温增、基于 PCR 的工作流程和基于 PCR 的工作流程在内的结果的解决方案。技术选择会影响检测週转时间、灵敏度、基础设施需求和实验室人员配备模式，进而影响各种临床环境中的部署模式。

终端使用者细分涵盖诊断实验室（包括医院实验室和参考实验室）、医院和诊所（包括二级和三级医院）、照护现场机构以及研究机构。不同终端使用者的采用趋势各不相同：高通量实验室优先考虑自动化和高通量，医院强调整合工作流程和照护现场能力，而研究机构则专注于灵活性和新型检测方法的实施。应用层级的差异包括自体免疫疾病检测（例如乳糜泻、狼疮和类风湿性关节炎） ；心臟病学检测（例如心臟标记和血脂谱）；传染病检查检测（例如 COVID-19、肝炎、HIV 和结核病）；神经病学诊断（例如阿兹海默症和帕金森氏症）；以及每种肿瘤学检测（包括血液学和固态肿瘤检测），每种肿瘤学检测的

检测类型（定性、定量、半定量）以及检体类型（血液、唾液、组织、尿液等）的差异会影响检测设计、监管分类和使用者培训要求。这种多方面的细分凸显了製定客製化商业策略的必要性，这些策略应使产品开发、监管规划、报销谈判和客户支援与每个细分市场的具体需求保持一致。

检验美洲、欧洲、中东和非洲以及亚太地区的区域市场动态如何影响产品采用、製造策略和市场进入途径。

区域趋势正在以不同的方式塑造美洲、欧洲、中东和非洲以及亚太地区的需求、创新中心和投资模式。在美洲，成熟的实验室网路和先进的报销系统持续推动对整合自动化、分子平台和资料管理解决方案的需求，而大型医院系统和参考实验室则需要可扩展的工作流程和检验的数位化整合。策略伙伴关係和在地化服务交付对于满足客户对快速安装、认证维护和持续试剂供应的期望变得日益重要。

在欧洲、中东和非洲地区，多样化的监管要求和医疗保健资金筹措模式既带来了复杂性，也带来了机会。该地区分散的市场结构有利于那些能够驾驭各种合格评估途径、证明其产品在多个医疗保健系统中具有临床效用并提供灵活商业模式的製造商。此外，对公共卫生基础设施和感染疾病监测的投资也推动了对分散式检查和强大的实验室参考检测能力的需求。

亚太地区既有成熟市场，也有新兴市场。分子诊断技术的快速普及、对就地检验的浓厚兴趣以及丰富的本地生产能力，正推动着日益激烈的市场竞争。区域供应链生态系统，包括组件供应商和试剂生产商，能够实现产品的快速本地化；而不同的临床实践模式和监管重点，则需要量身定制证据生成和市场进入策略。在所有地区，永续性考量、劳动力供应和数位基础设施都将继续影响部署时间表和客户预期。

了解製造商、软体供应商和服务供应商如何调整其产品组合、伙伴关係和供应链，以确保在诊断领域获得竞争优势。

为了抓住不断成长的诊断市场机会，产业领导者正积极寻求平台整合、策略合作以及以服务为中心的模式相结合的解决方案。製造商正投资于模组化仪器架构，以支援更广泛的检测项目，同时加快新检测产品的上市速度。此外，对试剂稳定性、标准化耗材介面和远距离诊断功能的配套投资，也透过提升运转率和整体成本透明度，增强了客户维繫。

软体和数据管理供应商正逐渐成为关键的合作伙伴，他们提供互通性层、云端分析和决策支援工具，以提升实验室产出的临床效用。这些供应商也与仪器製造商签订共同开发契约，提供承包解决方案，简化医疗机构的采购和整合流程。同时，服务机构也在拓展维护、培训和试剂生命週期管理项目，以使商业性奖励与实验室绩效指标保持一致。

策略性併购活动和联盟的建立将进一步影响竞争差异化，其目的在于弥合检测组合、地理覆盖范围和数位化能力方面的差距。能够展现可靠证据包、高效监管流程和健全上市后监测能力的公司，将在赢得与医疗系统和大型参考实验室的长期合约方面更具优势。卓越的供应链，包括多元化采购、在地化生产和敏捷物流，将继续成为商业性韧性和客户信任的关键因素。

为产业领导者提供可操作的策略重点，以协调产品架构、资料整合、证据产生和弹性供应链，加速产品普及。

为了在新一代诊断时代取得成功，产业领导者应优先考虑产品开发、供应链韧性、证据产生和市场推广策略的整合方法。首先，投资于模组化仪器设计和开放式耗材系统能够快速扩展检测范围，并减少对单一来源组件的依赖，从而能够快速回应临床需求和关税相关的供应中断。这种架构灵活性有助于与各种软体生态系统集成，并支援集中式和分散式环境中的混合部署模式。

接下来，透过将可互通的数据管理功能融入核心产品，强化您的数据策略。这包括采用行业数据标准、确保强大的网路安全，以及开发能够将实验室结果转化为可操作临床见解的分析技术。向支付方和医疗服务提供者展示资料整合如何改善临床路径和营运效率，对于获得他们的认可至关重要。

第三，我们制定了一套证据产生蓝图，该路线图超越了分析检验，涵盖了真实世界绩效评估、健康经济学评估和结果研究，以支持医保报销和临床指南纳入。我们与关键意见领袖、临床网路和参考实验室合作，产生符合监管机构和支付方期望的可重复的多中心数据。

最后，我们将积极重塑供应链和商业模式，以降低关税风险，包括将关键製造流程外包、实现供应商多元化，以及提供灵活的商业条款，例如试剂即服务和全面的维护合约。我们将优先采用以客户为中心的服务模式，强调运转率、培训和本地技术支持，以建立持久的客户关係并推动产品的长期应用。

我们解释了支撑这项分析的透明的、以访谈主导的、证据三角验证的调查方法，以确保可复製性和战略相关性。

本研究采用综合分析调查方法，旨在为策略决策提供坚实透明的基础。主要资料来源包括对临床实验室主任、医院采购主管、诊断研发主管和支付方进行结构化访谈，以收集关于技术需求、应用障碍和报销优先事项的第一线观点。这些定性见解与监管文件、同行评审文献、临床指南和行业公告等二手资料进行三角验证，以检验技术和商业趋势。

此分析方法利用交叉细分映射来评估产品类型、技术、最终用户、应用领域、测试类型和检体矩阵如何相互作用，从而影响产品采纳路径和商业化策略。此调查方法强调可重复性，透过记录资料来源、访谈程序和分析假设来实现，并对与供应链中断和政策变化相关的测试场景进行敏感度分析。

伦理考量和资料管治是研究途径不可或缺的一部分。用于二次分析的病患层级资料均已匿名化，透过访谈所获得的专有资讯也已匿名化，除非获得明确的署名许可。最终的综合分析旨在提供符合临床、监管和商业领域利益相关人员实际情况的、可信、透明且可操作的见解。

本文探讨了技术整合、实证策略和供应链韧性将如何决定诊断产业的未来竞争优势。

体外诊断领域的格局正因技术创新、不断演进的医疗服务模式和不断变化的政策趋势而重塑。能够成功驾驭这一格局的机构，将整合模组化产品设计、强大的数据策略和稳健的供应链，同时投资于必要的真实世界证据，以满足监管机构和医保报销相关人员的需求。仪器、试剂和软体之间的相互作用不断创造捆绑销售的机会，从而简化采购流程并提升临床效用。

区域差异和关税相关的供应链因素增加了商业性复杂性，但也为能够实现本地化生产、提供以服务为中心的商业模式并展现清晰的临床和经济价值的製造商创造了机会。包括实验室、医院/诊所、照护现场机构和研究机构在内的终端用户，将寻求能够提供可预测的性能、无缝整合和课责的服务模式的合作伙伴。

总之，诊断领域的下一个竞争优势将属于那些能够将技术能力转化为可部署解决方案，并使其与临床工作流程、支付方要求和实际营运情况相符的机构。对模组化平台、互通软体、在地化生产和实证医学的策略性投资，将为相关人员应对新兴临床需求并在诊断生态系统中实现永续发展奠定基础。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合人工智慧和机器学习演算法以提高照护现场诊断的敏感度和特异性
  • 开发一种多路復用微流体平台，用于同时检测单一患者检体中的多种生物标记
  • 在体外诊断设备中采用数位健康连接技术，实现即时远端监测和数据分析集成
  • 基于 CRISPR 的基因编辑技术在临床检体中超快速、高特异性检测致病核酸方面取得进展
  • 在新一代免疫检测中，新型奈米材料（如量子点和金奈米粒子）在讯号放大的应用日益广泛
  • 利用智慧型手机感应器扩展分散式居家传染病筛检分散式检查模式
  • 个人化医疗倡议的成长推动了对标靶治疗伴随诊断测试的需求。
  • 监管政策转变，强调对创新体外诊断技术制定严格的检验标准和快速核准流程。
  • 人们越来越关注永续的、一次性体外诊断试剂盒设计，以最大限度地减少生物危害废弃物和环境影响。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按产品类型分類的下一代体外诊断市场

  • 装置
    • 化学分析仪
    • 免疫检测装置
    • PCR装置
  • 试剂和套件
    • 临床化学试剂
    • 免疫检测试剂
    • 分子诊断剂
  • 软体和服务
    • 资料管理软体
    • 维护服务

第九章：按技术分類的下一代体外诊断市场

  • 临床化学
    • 电化学
    • 比色法
  • 免疫检测
    • CLIA
    • ELISA
    • FIA
  • 微生物学
    • 文化基础
    • 分子
  • 分子诊断
    • 等温扩增
    • 基于PCR的
    • 定序定序

第十章：按最终用户分類的下一代体外诊断市场

  • 诊断实验室
    • 医院检查室
    • 参考实验室
  • 医院和诊所
    • 二级护理医院
    • 三级医疗中心
  • 护理点
  • 研究所

第十一章 依应用分類的下一代体外诊断市场

  • 自体免疫疾病
    • 乳糜泻
    • 狼疮
    • 类风湿性关节炎
  • 心臟病学
    • 心臟标记物
    • 脂质
  • 感染疾病
    • 新型冠状病毒感染疾病（COVID-19）
    • 肝炎
    • HIV
    • 结核
  • 神经病学
    • 阿兹海默症
    • 帕金森氏症
  • 肿瘤学
    • 血液学
    • 固态肿瘤

第十二章：下一代体外诊断市场（依检测类型划分）

  • 定性
  • 定量
  • 半定量

第十三章：依检体类型分類的下一代体外诊断市场

  • 血
  • 唾液
  • 组织
  • 尿

第十四章：按地区分類的下一代体外诊断市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：按组别分類的下一代体外诊断市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：各国下一代体外诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Siemens Healthineers AG
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Sysmex Corporation
    • QIAGEN NV
    • Mindray Medical International Limited
Product Code: MRR-2E76C3E47F6A

The Next-Generation IVD Market is projected to grow by USD 100.20 billion at a CAGR of 5.43% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 65.60 billion
Estimated Year [2025] USD 69.24 billion
Forecast Year [2032] USD 100.20 billion
CAGR (%) 5.43%

Framing the urgent transformation in diagnostic strategy as technological convergence, regulatory evolution, and care delivery shifts redefine success for industry stakeholders

The current moment for in vitro diagnostics is defined by a rapid intersection of technological innovation, shifting care delivery models, and increasing demands for diagnostic speed, precision, and data integration. Clinical stakeholders are seeking diagnostic solutions that not only return accurate results but also integrate seamlessly into care pathways, support decentralized testing, and enable population-level surveillance. As molecular methods mature, digital health tools gain traction, and point-of-care modalities proliferate, organizations must reassess product roadmaps, partnerships, and supply chain strategies to remain relevant.

Regulatory frameworks and payer expectations are concurrently evolving, emphasizing clinical utility, real-world evidence, and interoperability. These changes are prompting manufacturers to invest more heavily in validation studies, quality management, and post-market data collection. Moreover, providers and laboratories are reconfiguring service delivery to balance centralized high-throughput testing with near-patient diagnostics, requiring flexible instrumentation, consumables strategies, and maintenance models.

Against this backdrop, competitive differentiation is increasingly driven by the ability to combine robust analytical performance with streamlined workflow, adaptable software, and service offerings that reduce total cost of ownership. Companies that effectively translate emerging science into clinically meaningful, easy-to-deploy solutions will capture influence across diagnostic laboratories, hospitals and clinic networks, point-of-care environments, and research institutions. The introduction to this analysis frames the core forces at play and sets the stage for deeper discussion of transformative shifts, trade policy impacts, segmentation insights, and regional considerations.

Identifying the pivotal technological and operational shifts that are disrupting traditional diagnostic models and creating new avenues for clinical impact and commercial differentiation

Several transformative shifts are fundamentally changing the trajectory of in vitro diagnostics, driven by technological convergence, new clinical priorities, and an emphasis on actionable data. First, molecular diagnostics have moved from specialized laboratories toward more routine clinical use, with polymerase chain reaction platforms and isothermal amplification technologies enabling faster, sensitive detection of infectious agents and genetic markers. This shift is accompanied by a renaissance in assay chemistry and reagent design that prioritizes robustness across decentralized settings.

Second, digital integration and data management have become core differentiators. The ability to harmonize instrument outputs with laboratory information systems, cloud-based analytics, and decision-support tools enhances diagnostic value by enabling longitudinal patient tracking, population surveillance, and AI-assisted interpretation. Interoperability standards and cybersecurity considerations are now central design criteria for both software vendors and instrument manufacturers.

Third, the expansion of point-of-care testing reflects changing care delivery models that emphasize rapid diagnosis in outpatient clinics, emergency departments, and community settings. This trend is reshaping product engineering to focus on portability, simplified workflows, and low-maintenance operation. Concurrently, service models are evolving to include outcome-linked maintenance, remote diagnostics, and subscription-based reagent supply that align incentives across providers and vendors.

Finally, regulatory and reimbursement landscapes are adapting to accommodate innovative assays and digital diagnostics, driving manufacturers to generate not only analytical validation but also real-world clinical evidence. Together, these shifts demand an integrated commercial approach that balances innovation with pragmatic considerations around supply chains, manufacturing scalability, and post-market support.

Analyzing how recent United States tariff measures have reshaped sourcing, pricing structures, and supply chain resilience across the diagnostic instrument and reagent lifecycle

The cumulative impact of United States tariff actions in 2025 is exerting multidimensional pressure across the diagnostics value chain, prompting reassessment of sourcing, pricing, and localization strategies. Tariffs on key instrument components, reagent raw materials, and finished goods have amplified input cost volatility, intensifying procurement complexity for manufacturers and laboratories alike. In response, many firms are revisiting supplier networks to mitigate exposure to tariff-exposed geographies and are accelerating diversification of manufacturing footprints.

Beyond immediate cost implications, tariffs have affected capital equipment purchasing behavior. Healthcare organizations evaluating instrumentation purchases are factoring in extended total cost considerations, including potential import duties, logistical lead times, and maintenance parts availability. This has increased interest in domestically produced instruments or devices whose critical subcomponents originate in tariff-neutral jurisdictions, as well as in service contracts that include parts and reagent predictability to offset tariff-driven price fluctuations.

Strategically, tariffs have propelled a renewed focus on supply chain resilience and vertical integration. Companies are exploring onshoring of critical reagent production and localized assembly to stabilize delivery timelines and maintain competitive positioning. At the same time, regional regulatory and trade policy responses have introduced administrative complexity, with manufacturers required to manage differing compliance pathways and documentation to qualify for tariff exemptions or preferential treatment.

Taken together, the tariff environment in 2025 has shifted decision-making from short-term procurement arbitrage toward longer-term supply chain redesigns, supplier partnerships, and product strategies that emphasize modularity, local support, and predictable lifecycle economics.

Unpacking multidimensional segmentation across product, technology, end-user, application, test type, and sample type to reveal targeted commercialization imperatives and clinical priorities

A granular segmentation approach reveals differentiated requirements, adoption patterns, and commercialization pathways across product types, technologies, end users, applications, test types, and sample types. By product type, the landscape includes instruments-such as chemistry analyzers, immunoassay analyzers, and PCR instruments-alongside reagents and kits that span clinical chemistry reagents, immunoassay reagents, and molecular diagnostics reagents, and finally software and services comprised of data management platforms and maintenance services. Each product class demands distinct go-to-market models: instruments require capital sales, reagents depend on recurring consumption and supply chain optimization, and software and services center on integration and lifecycle revenue.

Technology segmentation highlights the diversity of underlying modalities, including clinical chemistry platforms that rely on electrochemical or photometric detection, immunoassay systems utilizing CLIA, ELISA, or FIA formats, microbiology approaches that range from culture-based methods to molecular assays, and molecular diagnostic techniques that include isothermal amplification, PCR-based workflows, and sequencing-based solutions. Technology choices influence assay turnaround time, sensitivity, infrastructure requirements, and laboratory staffing models, which in turn shape adoption across different clinical settings.

End-user segmentation spans diagnostic laboratories-both hospital laboratories and reference laboratories-hospitals and clinics that include secondary care hospitals and tertiary care centers, point-of-care locations, and research institutes. Adoption dynamics vary by end user, with high-throughput labs prioritizing automation and throughput, hospitals emphasizing integrated workflows and point-of-care responsiveness, and research institutes focusing on flexibility and novel assay adoption. Application-level differentiation includes autoimmune disease testing across celiac, lupus, and rheumatoid arthritis; cardiology assays such as cardiac markers and lipid panels; infectious disease testing for COVID-19, hepatitis, HIV, and tuberculosis; neurology diagnostics for Alzheimer's and Parkinson's disease; and oncology covering hematological and solid tumor testing, each with unique clinical evidence and regulatory pathways.

Test type distinctions-qualitative, quantitative, and semi-quantitative-combined with sample type considerations like blood, saliva, tissue, and urine, further influence assay design, regulatory classification, and user training requirements. This multifaceted segmentation underscores the necessity for tailored commercial strategies that align product development, regulatory planning, reimbursement engagement, and customer support with the specific demands of each segment.

Examining how regional market dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific are influencing adoption, manufacturing strategies, and market access paths

Regional dynamics are shaping demand, innovation hubs, and investment patterns in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established laboratory networks and advanced reimbursement frameworks continue to drive demand for integrated automation, molecular platforms, and data management solutions, while large hospital systems and reference laboratories push for scalable workflows and validated digital integrations. Strategic partnerships and localized service offerings are increasingly important to meet customer expectations for rapid installation, certified maintenance, and reagent continuity.

In the Europe, Middle East & Africa region, heterogeneous regulatory requirements and diverse healthcare financing models create both complexity and opportunity. The region's fragmented market structure rewards manufacturers who can navigate varied conformity assessment pathways, demonstrate clinical utility across multiple health systems, and offer flexible commercial models. Moreover, investment in public health infrastructure and infectious disease surveillance is prompting demand for both decentralized testing and robust laboratory reference capabilities.

Asia-Pacific presents a mosaic of mature and emerging markets where rapid adoption of molecular diagnostics, strong interest in point-of-care modalities, and substantial local manufacturing capacity are driving competitive intensity. Regional supply chain ecosystems, including component suppliers and reagent manufacturers, are enabling faster product localization, while differing clinical practice patterns and regulatory priorities require tailored evidence generation and market access approaches. Across all regions, sustainability considerations, workforce availability, and digital infrastructure will continue to influence deployment timelines and customer expectations.

Identifying how manufacturers, software vendors, and service providers are aligning portfolios, partnerships, and supply chains to secure competitive advantage in diagnostics

Leading industry players are pursuing a mix of platform consolidation, strategic partnerships, and service-centric models to capture expanding diagnostic opportunities. Manufacturers are investing in modular instrument architectures that support a broad assay menu while reducing time to market for new tests. Complementary investments in reagent stability, standardized consumable interfaces, and remote diagnostics capabilities are enhancing customer retention through improved uptime and total cost clarity.

Software and data management providers are emerging as pivotal collaborators, offering interoperability layers, cloud analytics, and decision-support tools that increase the clinical utility of laboratory outputs. These vendors are also engaging in co-development arrangements with instrument manufacturers to deliver turnkey solutions that simplify procurement and integration for healthcare providers. At the same time, service organizations are expanding maintenance, training, and reagent lifecycle programs to align commercial incentives with laboratory performance metrics.

Competitive differentiation is further influenced by strategic M&A activity and alliance formation aimed at closing gaps in assay portfolios, geographic presence, and digital capabilities. Companies that can demonstrate credible evidence packages, efficient regulatory pathways, and robust post-market surveillance are better positioned to secure long-term contracts with health systems and large reference laboratories. Supply chain excellence-including diversified sourcing, localized manufacturing, and responsive logistics-remains a critical determinant of commercial resilience and customer trust.

Actionable strategic priorities for industry leaders to align product architecture, data integration, evidence generation, and resilient supply chains to accelerate adoption

Industry leaders should prioritize an integrated approach that aligns product development, supply chain resilience, evidence generation, and go-to-market strategies to succeed in the next-generation diagnostics era. First, invest in modular instrument designs and open consumable systems that allow rapid assay expansion and reduce dependence on single-source components, thereby enabling faster response to clinical needs and tariff-related supply disruptions. This architectural flexibility will also facilitate integration with diverse software ecosystems and support hybrid deployment models across centralized and decentralized settings.

Second, strengthen data strategies by embedding interoperable data management capabilities into core offerings. This involves adopting industry data standards, ensuring robust cybersecurity, and developing analytics that translate laboratory outputs into actionable clinical insights. Demonstrating how data integration improves clinical pathways and operational efficiency will be essential for payer and provider adoption.

Third, develop evidence generation roadmaps that extend beyond analytical validation to include real-world performance, health economic assessments, and outcomes studies that support reimbursement and clinical guideline inclusion. Collaborate with key opinion leaders, clinical networks, and reference laboratories to generate reproducible multi-center data that aligns with regulatory and payer expectations.

Finally, proactively redesign supply chain and commercial models to mitigate tariff exposure, including nearshoring critical manufacturing, diversifying suppliers, and offering flexible commercial terms such as reagent-as-a-service or bundled maintenance agreements. Prioritize customer-centric service frameworks that emphasize uptime, training, and local technical support to build durable customer relationships and unlock long-term adoption.

Describing the transparent, interview-led, and evidence-triangulated research methodology underpinning the analysis to ensure reproducibility and strategic relevance

This research synthesis integrates a multi-source, evidence-based methodology designed to provide a robust and transparent foundation for strategic decision-making. Primary inputs include structured interviews with clinical laboratory directors, hospital procurement leaders, diagnostic R&D heads, and payers to capture first-hand perspectives on technology requirements, adoption barriers, and reimbursement priorities. These qualitative insights are triangulated with secondary sources such as regulatory filings, peer-reviewed literature, clinical guidelines, and industry announcements to validate technological trends and commercial movements.

Analytical approaches employ cross-segmentation mapping to assess how product types, technologies, end users, applications, test types, and sample matrices interact to influence adoption pathways and commercialization tactics. The methodology prioritizes reproducibility by documenting data provenance, interview protocols, and analytic assumptions, while sensitivity analyses are applied to scenario testing related to supply chain disruptions and policy changes.

Ethical considerations and data governance are integral to the research approach, ensuring that patient-level data used in secondary analysis are de-identified and that proprietary information obtained through interviews is anonymized unless explicit permission for attribution was provided. The resulting synthesis aims to deliver actionable insights that are defensible, transparent, and aligned with stakeholder realities across clinical, regulatory, and commercial domains.

Concluding synthesis on how technological integration, evidence strategies, and supply chain resilience will determine future competitive advantage in diagnostics

The trajectory of in vitro diagnostics is being reshaped by a convergence of technological innovation, evolving care delivery models, and shifting policy dynamics. Organizations that successfully navigate this landscape will be those that integrate modular product design, robust data strategies, and resilient supply chains while investing in the real-world evidence necessary to satisfy regulatory and reimbursement stakeholders. The interplay of instrumentation, reagents, and software continues to create opportunities for bundled offerings that simplify procurement and enhance clinical utility.

Regional differentiation and tariff-related supply chain considerations add layers of commercial complexity, but they also create openings for manufacturers that can localize production, offer service-centric commercial models, and demonstrate clear clinical and economic value. End users across diagnostic laboratories, hospitals and clinics, point-of-care settings, and research institutes will seek partners who can deliver predictable performance, seamless integration, and accountable service models.

In conclusion, the next wave of competitive advantage in diagnostics will be earned by organizations that translate technical capability into deployable solutions aligned with clinical workflows, payer requirements, and operational realities. Strategic investments in modular platforms, interoperable software, localized manufacturing, and evidence generation will position stakeholders to meet emerging clinical demands and capture sustained relevance in the diagnostic ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence and machine learning algorithms to improve sensitivity and specificity of point-of-care IVD diagnostics
  • 5.2. Development of multiplexed microfluidic platforms enabling simultaneous detection of multiple biomarkers in a single patient sample
  • 5.3. Adoption of digital health connectivity in IVD devices for real-time remote monitoring and data analytics integration
  • 5.4. Advancement of CRISPR-based gene editing techniques for ultrafast highly specific detection of pathogenic nucleic acids in clinical samples
  • 5.5. Rising use of novel nanomaterials such as quantum dots and gold nanoparticles for signal amplification in next-generation immunoassays
  • 5.6. Expansion of decentralized testing models leveraging smartphone-based sensors for at-home infectious disease screening
  • 5.7. Growth of personalized medicine initiatives driving demand for companion diagnostic assays tailored to targeted therapies
  • 5.8. Regulatory shifts emphasizing stringent validation standards and accelerated approval pathways for innovative IVD technologies
  • 5.9. Increasing focus on sustainable and disposable IVD cartridge designs to minimize biohazard waste and environmental footprint

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next-Generation IVD Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Chemistry Analyzers
    • 8.1.2. Immunoassay Analyzers
    • 8.1.3. PCR Instruments
  • 8.2. Reagents & Kits
    • 8.2.1. Clinical Chemistry Reagents
    • 8.2.2. Immunoassay Reagents
    • 8.2.3. Molecular Diagnostics Reagents
  • 8.3. Software & Services
    • 8.3.1. Data Management Software
    • 8.3.2. Maintenance Services

9. Next-Generation IVD Market, by Technology

  • 9.1. Clinical Chemistry
    • 9.1.1. Electrochemical
    • 9.1.2. Photometric
  • 9.2. Immunoassay
    • 9.2.1. Clia
    • 9.2.2. Elisa
    • 9.2.3. Fia
  • 9.3. Microbiology
    • 9.3.1. Culture Based
    • 9.3.2. Molecular
  • 9.4. Molecular Diagnostic
    • 9.4.1. Isothermal Amplification
    • 9.4.2. PCR Based
    • 9.4.3. Sequencing Based

10. Next-Generation IVD Market, by End User

  • 10.1. Diagnostic Laboratories
    • 10.1.1. Hospital Laboratories
    • 10.1.2. Reference Laboratories
  • 10.2. Hospitals & Clinics
    • 10.2.1. Secondary Care Hospitals
    • 10.2.2. Tertiary Care Centers
  • 10.3. Point Of Care
  • 10.4. Research Institutes

11. Next-Generation IVD Market, by Application

  • 11.1. Autoimmune Diseases
    • 11.1.1. Celiac
    • 11.1.2. Lupus
    • 11.1.3. Rheumatoid Arthritis
  • 11.2. Cardiology
    • 11.2.1. Cardiac Markers
    • 11.2.2. Lipids
  • 11.3. Infectious Diseases
    • 11.3.1. Covid-19
    • 11.3.2. Hepatitis
    • 11.3.3. Hiv
    • 11.3.4. Tuberculosis
  • 11.4. Neurology
    • 11.4.1. Alzheimer's Disease
    • 11.4.2. Parkinson's Disease
  • 11.5. Oncology
    • 11.5.1. Hematological
    • 11.5.2. Solid Tumor

12. Next-Generation IVD Market, by Test Type

  • 12.1. Qualitative
  • 12.2. Quantitative
  • 12.3. Semi Quantitative

13. Next-Generation IVD Market, by Sample Type

  • 13.1. Blood
  • 13.2. Saliva
  • 13.3. Tissue
  • 13.4. Urine

14. Next-Generation IVD Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Next-Generation IVD Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Next-Generation IVD Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. F. Hoffmann-La Roche Ltd.
    • 17.3.2. Abbott Laboratories
    • 17.3.3. Siemens Healthineers AG
    • 17.3.4. Danaher Corporation
    • 17.3.5. Thermo Fisher Scientific Inc.
    • 17.3.6. Becton, Dickinson and Company
    • 17.3.7. bioMerieux SA
    • 17.3.8. Sysmex Corporation
    • 17.3.9. QIAGEN N.V.
    • 17.3.10. Mindray Medical International Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION IVD MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS NEXT-GENERATION IVD MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION IVD MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NEXT-GENERATION IVD MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. NEXT-GENERATION IVD MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEXT-GENERATION IVD MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEXT-GENERATION IVD MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION IVD MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CHEMISTRY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CHEMISTRY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CHEMISTRY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CHEMISTRY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CHEMISTRY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CHEMISTRY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTICS REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTICS REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTICS REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTICS REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTICS REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTICS REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MAINTENANCE SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MAINTENANCE SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MAINTENANCE SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MAINTENANCE SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELECTROCHEMICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELECTROCHEMICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELECTROCHEMICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELECTROCHEMICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELECTROCHEMICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELECTROCHEMICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PHOTOMETRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PHOTOMETRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PHOTOMETRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PHOTOMETRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PHOTOMETRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PHOTOMETRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CLIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY FIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY FIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY FIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY FIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY FIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY FIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CULTURE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CULTURE BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CULTURE BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CULTURE BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY MOLECULAR DIAGNOSTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY PCR BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEQUENCING BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEQUENCING BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEQUENCING BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEQUENCING BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEQUENCING BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SEQUENCING BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY SECONDARY CARE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TERTIARY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TERTIARY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TERTIARY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TERTIARY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TERTIARY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TERTIARY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CELIAC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CELIAC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CELIAC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CELIAC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CELIAC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CELIAC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LUPUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LUPUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LUPUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LUPUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LUPUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LUPUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIAC MARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIAC MARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIAC MARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY CARDIAC MARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LIPIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LIPIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LIPIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LIPIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LIPIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY LIPIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COVID-19, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COVID-19, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COVID-19, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COVID-19, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COVID-19, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY COVID-19, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEPATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEPATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TUBERCULOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TUBERCULOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TUBERCULOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY TUBERCULOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL NEXT-GENERATION IVD MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)

TA